Related Experiment Video
Updated: Mar 15, 2026
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective
Leàn Rolfes1,2, Judith Kolfschoten3, Florence van Hunsel1,2
1Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Background:
There is limited information on actions taken in response to drug safety signals originating from a spontaneous reporting system (SRS) in pharmacovigilance. In The Netherlands the Pharmacovigilance Centre Lareb is an independent organization that works in close collaboration with the Dutch regulatory agency, the Medicines Evaluation Board (MEB).
Objective:
The objective of this study is to gain insight in steps undertaken on signals originating from the SRS and disseminated by Lareb from 2008-2012.
Method:
For all signals the recommendations of Lareb and the following steps proposed by the MEB were analyzed. Secondary outcomes were prioritization of the signal, the year of dissemination and if Lareb published (inter)nationally about the signal. Pearson's Chi-square (X2) and Mantel-Haenszel statistics were used for statistical analysis.
Results:
Of all signals disseminated by Lareb from 2008-2012, 90,7% resulted in an action: in 87% a regulatory action and in 36% an (inter)national publication. Generally, Lareb's recommendations correspond to steps undertaken by the MEB.
Conclusion:
This study found influence of signal prioritization on Lareb's recommendations but not on the steps undertaken by the MEB. Trends over time were only seen for steps undertaken by the MEB. These differences are most probably due to responsibilities of the different EU member states of various drugs.
